Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Amortization of Deferred Charges (2022 - 2025)

Tarsus Pharmaceuticals has reported Amortization of Deferred Charges over the past 4 years, most recently at $156000.0 for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $156000.0 for Q4 2025, up 13.04% from a year ago — trailing twelve months through Dec 2025 was $593000.0 (up 23.03% YoY), and the annual figure for FY2025 was $593000.0, up 47.51%.
  • Amortization of Deferred Charges for Q4 2025 was $156000.0 at Tarsus Pharmaceuticals, up from $152000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for TARS hit a ceiling of $156000.0 in Q4 2025 and a floor of $28000.0 in Q2 2023.
  • Median Amortization of Deferred Charges over the past 4 years was $78000.0 (2022), compared with a mean of $85125.0.
  • Biggest five-year swings in Amortization of Deferred Charges: crashed 47.27% in 2023 and later surged 345.16% in 2024.
  • Tarsus Pharmaceuticals' Amortization of Deferred Charges stood at $30000.0 in 2022, then grew by 3.33% to $31000.0 in 2023, then surged by 345.16% to $138000.0 in 2024, then rose by 13.04% to $156000.0 in 2025.
  • The last three reported values for Amortization of Deferred Charges were $156000.0 (Q4 2025), $152000.0 (Q3 2025), and $146000.0 (Q2 2025) per Business Quant data.